SoundHealth closed a Series A round led by Shangbay Capital to expand its FDA-cleared acoustic resonance wearable devices for treating allergic rhinitis and sleep disorders.
- Amount
- $12.3M
- Stage
- Series A
- Announced
- 28 July 2026
- Lead
- Shangbay Capital
- Use of funds
- Accelerate growth of its portfolio of personalized, FDA-cleared therapeutics and commercialization of the Sonu device, and advance acoustic sleep health applications.
- Total raised
- $12.3M to date
- Checked
- Amount and date checked against the press source